Fig. 1From: 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse gliomaPatient recruitment pathway. A total of 168 patients were screened, and 107 patients were included in the current study. Patients were randomly assigned to the primary or validation cohortBack to article page